Plethora Solutions

• 12/04/13

  Directorate Change

• 04/04/13

  Result of GM

• 18/03/13

  Placing to raise ?2.124m

• 15/03/13

  Holding(s) in Company

• 25/02/13

  Strategic review of The Urology Company Limited

• 

  12/04/13

  Mellon takes interim chair at Plethora Solutions

• 

  18/03/13

  Plethora Solutions thrown £2.1mln lifeline

• 

  25/02/13

  Plethora Solutions says urgent funding plans are nearing completion

• 

  14/02/13

  Plethora Solutions' fund raising talks at an advanced stage

• 

  05/02/13

  UPDATE: Plethora Solutions in financing talks

• 

  05/02/13

  Plethora Solutions in financing talks

• 

  15/10/12

  Plethora Solutions' PSD502 product progressing towards approval before schedule, says broker

• 

  28/09/12

  Plethora Solutions remains in dialogue with potential partners

• 

  14/06/12

  Plethora raises £350,000; Jim Mellon ups stake to 12 per cent

• 

  11/06/12

  UPDATE - Plethora Solutions submits dossier for key drug to European regulators

  Plethora Solutions’ latest update on its key treatment is “huge news”, chief executive Ronald Openshaw told Proactive Investors.

• 

  12/06/2012

  Stocktube video - Plethora Solutions now focused on commercialisation of its premature ejaculation treatment

  Ronald Openshaw, CEO at Plethora Solutions (LON:PLE), tells Proactiveinvestors that the early submission of the dossier to the European Medicines Agency for the approval of the premature ejaculation treatment PSD502 is “huge news”. Ronald says that it’s likely to take 12-18 months for approval then it’s the launch. Ahead of that then management will look at a partnering agreement which it is anticipated will contain upfront, milestone and royalty payments.

• 

  02/05/13

  FTSE 100 ends up after choppy day
• 

  02/05/13

  US shares advance on positive jobs data
• 

  02/05/13

  FTSE 100 on the up ahead of ECB meet
• 

  05/04/13

  FTSE 100 takes a battering after US jobs data
• 

  18/03/13

  Proactive news summary, featuring Telit, Gasol, Kedco, Deltex, Plethora, Magnolia Petroleum, San Leon

• 20/07/11

  Press: 20.07.11: -1.62, (4.38) Press: Plethora Solutions fell on news that full-year results would be lower than expected. Source - Financial Times

  Press: 20.07.11: -1.62, (4.38) Press: Plethora Solutions fell on news that full-year results would be lower than expected. Source - Financial Times
• 03/12/10

  Press: 03.12.10: -0.75, (10.25) Press: Plethora Solutions lost ground following a placing of 8.23m shares at 8.5p. The GBP750,000 raised is to... read more

  Press: 03.12.10: -0.75, (10.25) Press: Plethora Solutions lost ground following a placing of 8.23m shares at 8.5p. The GBP750,000 raised is to be used for general working capital. There were also industry rumours that it will soon announce a major licensing deal for one of its female health products with a leading UK retailer. Source - Mail
• 08/09/10

  +1.50 +13.00

  an article in the Mail reports: Plethora Solutions rose 0.5p to 11.5p. Broker FinnCap, which has a target price of 57p, says the company already has five products in... read more

  an article in the Mail reports: Plethora Solutions rose 0.5p to 11.5p. Broker FinnCap, which has a target price of 57p, says the company already has five products in the market with a further eight reckoned to come on board before the end of 2010. The paper suggests that this is "a firm foundation for a profitable urology business".
• 27/04/10

  +0.00 +14.75

  the U.K. launch of Johnson & Johnson?s (JNJ) premature ejaculation pill Priligy highlights the prospects for Plethora Solutions? (PLE.LN) premature ejaculation spray PSD502, says FinnCap analyst Keith Redpath. Priligy has gone on sale for GBP25 a tablet, and if 33,000 men took one a month sales would hit GBP10 million a year, he says. Notes 33,000 men represent less than 0.2% of the estimated U.K. male population affected by the condition. PSD502 has advantages over Priligy: it has fewer side effects and is effective within seconds, not hours, Redpath says. PSD502 launch is expected in 12 to 18 months. Has 57p target.

  the U.K. launch of Johnson & Johnson?s (JNJ) premature ejaculation pill Priligy highlights the prospects for Plethora Solutions? (PLE.LN) premature ejaculation spray PSD502, says FinnCap analyst Keith Redpath. Priligy has gone on sale for GBP25 a tablet, and if 33,000 men took one a month sales would hit GBP10 million a year, he says. Notes 33,000 men represent less than 0.2% of the estimated U.K. male population affected by the condition. PSD502 has advantages over Priligy: it has fewer side effects and is effective within seconds, not hours, Redpath says. PSD502 launch is expected in 12 to 18 months. Has 57p target.
• 09/03/10

  +0.00 +15.00

  Plethora Solutions Holdings PLC said its Urology Company Ltd. unit has four products in its portfolio and will launch between six and... read more

  Plethora Solutions Holdings PLC said its Urology Company Ltd. unit has four products in its portfolio and will launch between six and nine this year. The unit, which was established last year to sell urology products in the U.K., secured the distribution rights to hypogonadism treatment Striant and obstetric gel Dianatal, and Plethora Chief Executive Steven Powell told Dow Jones Newswires the unit has two other products in its portfolio. He declined to name them, but said one is a male health product and the other is for urinary tract infections. Powell said Plethora has identified three other products it wants to add to its Urology Company unit and intends to launch up to nine products this year, possibly by the end of the third quarter. Powell said the unit is expected to make a small loss in 2010, weighed on by start up costs, but will be profitable thereafter.

Plethora Solutions is a speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders.

The diagnosis and treatment of urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices.

Clinical Specialism

Sexual Dysfunction

Sexual dysfunction can arise from a variety of psychological and physical factors and encompasses the loss of sexual desire, pain during intercourse and the inability to obtain an erection (erectile dysfunction) or to enjoy or achieve orgasm. About 30 to 50% of women experience sexual dysfunction at some time during their life, while 20-30% of men will experience problems such as erectile dysfunction and premature ejaculation.

Speciality Areas

Premature Ejaculation

Erectile Dysfunction

hI- Argenol

Uro-gynaecology

Uro-gynaecology is a sub-speciality of gynaecology which deals specifically with bladder and pelvic floor problems in women. While there are treatments for most of these conditions, many have limited efficacy and this field therefore constitutes an area of high poorly met medical need.

Intersistital Cystitis

Dysmenorrhoea & Gynaecological Pain

Urinary Incontinence

Urinary incontinence (UI) is a condition where involuntary loss of urine is a social or hygienic problem. UI may be broadly divided into stress UI (SUI) and urge UI (UUI) although “mixed” incontinence is not uncommon. 

Urinary incontinence affects both men and women. SUI is more commonly diagnosed in women and is associated with anatomical stresses caused by pregnancy and childbirth. Men may experience UUI as a result of prostate enlargement.

Stress Incontinence

Urge Urinary Incontinence

The Urology Company

The Urology Company is the marketing subsidiary of Plethora Solutions. The primary aim of the business is to work with partner companies internationally to provide healthcare professionals and patients in the UK with a comprehensive range of products for the treatment of urological disorders.

In particular the Company will focus on products for the treatment and management of urinary incontinence, obstetric and gynaecological conditions, urological pain, prostatic disease and male sexual dysfunction. The product portfolio comprises proprietary and generic pharmaceutical products and OTC products.

For further information on The Urology Company please click here 

People

Plethora has brought together a dedicated team of people who have grown the company through their commitment and hard work. It has a Board of Directors and Executive Management Team with proven business, legal, financial and pharmaceutical industry backgrounds, offering the expertise for successful development and commercialisation of pharmaceutical products.

The Management Team

Mr Ronald Openshaw (Chief Executive Officer)

Ronald Openshaw has a significant track record in life sciences and healthcare sectors both in executive management and in an advisory role. He is the founder of the M&A and strategic consulting firm Lucia Capital LLP and previously he spent many years as an investment banker at Panmure Gordon & Co. Limited (latterly WestLB Panmure Limited) and then most recently Jefferies International Limited. He also served as CFO and acting CEO at Pharmagene plc until its merger with Asterand plc in 2006, where he remained as CFO to complete the integration in early 2007. Ronald qualified as a Chartered Accountant with KPMG.

Dr. Michael Wyllie (Chief Scientific Officer)

Mike Wyllie is a co-founder of Plethora. He has over 25 years of experience in senior management level positions within the pharmaceutical industry with American Home Products and Pfizer. He has considerable hands-on experience in all aspects of the drug discovery and development process and has been involved with new project inception, drug discovery and safety testing, early and late stage clinical development, regulatory filing and the successful commercialisation of products including Cardura® (doxazosin) and Viagra® (sildenafil). Dr. Wyllie sits on The Clinical Trial Design and Future Therapies in BPH Committees of the World Health Organisation International Consultations on Urological Disease and he is an assistant editor of the British Journal of Urology in the Sexual Medicine Section. He has over 100 publications and is named as the inventor of over 80 patents.

Plethora Solutions Holdings plc